Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the company’s bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont
Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the companys bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont Pharmaceuticals to expedite the changeover, according to the company. North Billerica, MA-based Du Pont will continue to manufacture Quadramet.
The two companies initiated an interim agreement June 2 in which they determined that Du Pont would identify marketing partner candidates for Cytogen (SCAN Special Report 6/98). The agreement has been extended through the end of this month, pending the final selection of a new partner and the completion of Cytogens marketing arrangements with Du Pont. Cytogen has taken over the identification and selection of candidates as the process continues.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.